Guadecitabine in higher-risk MDS/CMML: a Phase II trial [Video]

Samuel Urrutia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II trial evaluating guadecitabine in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), which were classified according to the World Health Organization (WHO) 2022 criteria. After a median follow-up of 14 months, the median overall survival (OS) was 16 months, although TP53 mutations affected responses. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.